Skip to main content

AIBiotics Therapies, Inc.

corporate_fare Company Profile

AIBiotics Therapies, Inc.

AIBT·OTC·Life Sciences·CIK 0001763329

Aibotics, Inc. focuses on the study of psychedelics for treating mental health issues and supports the creation of both natural and synthetic molecules for developing treatments. The company plans to use technology from its parent company, Ehave, Inc., to collect research and clinical data to further study the effects of psychedelics in mental health treatment. Through the acquisition of assets from Philon Labs, Aibotics intends to use Artificial Intelligence (AI) to transform ideas and solutions into products using advanced engineering and design techniques, aiming to enhance patient care and streamline medical processes. Aibotics, Inc. was incorporated in Nevada on January 21, 2000, as RM Investors, Inc. In March 2014, it acquired 100% of 20/20 Produce Sales, Inc., an Idaho corporation incorporated on December 22, 1994. On March 26, 2014, the company increased its authorized common stock to 100,000,000 shares, par value $0.001, and authorized 5,000,000 shares of preferred stock, par value $0.001. In December 2020, the company entered into agreements to purchase all outstanding stock of Aibotics, Inc. from Ehave, Inc. In May 2021, the company changed its name to Aibotics Therapies Inc. Its trading symbol is TPIA. The company has one subsidiary, Aibotics Therapies Inc., a Florida corporation.

AIBiotics Therapies, Inc. (OTC:AIBT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 9 items for AIBT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 8/10. Across its 9 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for AIBT spans 10-Q, 8-K, 10-K.

Recent high-impact activity:

  • AIBiotics Q3 10-Q: Going Concern Reaffirmed, Material Weakness Disclosed, Share Count Tops 1 Billion
  • Aibotics Closes NovaCore Labs Asset Buy; Issues 100M Shares to Two Executives
  • Aibotics to Acquire Empulser Enterprises for Up to $22M in Series C Preferred Stock
  • Aibotics Q2 Loss Widens; Working Capital Deficit Hits $4.9M, Shares Outstanding Surge 48%
  • AIBOTICS Reports Zero Revenue, $418K Net Loss in Q1 2026

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$2.18K
Net Income
-$2.22M
Op. Cash Flow
-$458.24K
Gross Profit
$2.18K
Operating Income
-$1.84M
Cash & Equivalents
$255.94K
Debt / Equity
0.00×
Net Margin
-1015.00×
Shares Outstanding
486.9M sh
Source: 10-K · filed 2026-04-15 · accession 0001096906-26-000555

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 80,439 shares in AIBT as of the October 30, 2026 settlement, a 81.4% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 79.5% of AIBT volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)80,439 shares as of October 30, 2026
Change vs prior period▼ 81.4%
Days to cover1.00 at avg daily volume of 40,712,684
Daily short volume (FINRA facilities)79.5% of 6,077,134 shares on November 20, 2026
5-day average short volume55.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with A →
$0.0029 -3.33% today
52-week range · as of 2026-11-20 $0.0003 – $0.0169
Market cap
$2.58M
Volume
6.1M (0.4× avg)
3-mo avg 15.2M
Live data · 2026-11-22 08:33 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed AIBT - Latest Insights

AIBT
Nov 20, 2026, 5:12 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.0029
Real-time Price: $0.0029 info
Change: $0 (0%) info
Market Cap: $2.581M info
AIBT
Oct 16, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.0021
Real-time Price: $0.0029 info
Change: +$0.0008 (+38%) info
Market Cap: $2.581M info
AIBT
Oct 02, 2026, 6:50 PM EDT
Filing Type: 8-K
Importance Score:
8
Updated Oct 5, 7:02 AM ET — AIBotics agreed to acquire Empulser for up to 2.2M Series C Preferred shares ($22M stated value), with Patrick Tsang joining as Strategic A…
Price at Filing: $0.0022
Real-time Price: $0.0029 info
Change: +$0.0007 (+32%) info
Market Cap: $2.581M info
AIBT
Aug 19, 2026, 5:25 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.0004
Real-time Price: $0.0029 info
Change: +$0.0025 (+625%) info
Market Cap: $2.581M info
AIBT
Jun 09, 2026, 6:11 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.0009
Real-time Price: $0.0029 info
Change: +$0.0020 (+222%) info
Market Cap: $2.581M info
AIBT
Jun 08, 2026, 7:12 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.0009
Real-time Price: $0.0029 info
Change: +$0.0020 (+222%) info
Market Cap: $2.581M info
AIBT
May 19, 2026, 9:45 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.0007
Real-time Price: $0.0029 info
Change: +$0.0022 (+314%) info
Market Cap: $2.581M info
AIBT
Apr 30, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.0011
Real-time Price: $0.0029 info
Change: +$0.0018 (+164%) info
Market Cap: $2.581M info
AIBT
Apr 15, 2026, 4:20 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $0.0011
Real-time Price: $0.0029 info
Change: +$0.0018 (+164%) info
Market Cap: $2.581M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets